THE ROLE OF CANNABIDIOL IN THE INFLAMMATORY PROCESS AND ITS PROPERTIES AS AN ALTERNATIVE THERAPY – A REVIEW (META-ANALYSIS)
Cannabis has been used as a medicinal plant for thousands of years in Asia. Numerous physical, psychological, and emotional benefits have been attributed to cannabis since its first reported use in 2,600 BC in a Chinese pharmacopoeia. Recent years have seen a resurgence in interest in the therapeutic potential of compounds derived from these plants, mainly the non-psychoactive compound cannabidiol (CBD). In this way, we seek to evaluate, through this present study, what has been published about CBD in the Pubmed / Medline database in the last two years (2019/2020) in relation to anxiety, depression, panic attack and dementia, as well as therapeutic dosages, results with significant values, side effects and others reported in the studies found. The results were distributed in 4 tables. In the first, the types of publication were reported; in the second, the proposal for evaluation; in the third, the results with significance evaluated; and in the fourth the doses used. Although the majority of studies found are in the form of a review (55.3%), several studies in humans have shown promising results with the use of CBD in therapies. The treatments for anxiety and stress with CBD were the most evident accounting for 37.8% of the total studies found in table 2. The relationship of CBD in metabolic processes as inflammatory markers, activator of specific nuclear receptors and protein modulations was the second most evident item na tabela 2 with 11,1%. Cognitive processes and depression appear comes in sequence with 8.9% both. The results of significance values found in this study demonstrated a good acceptance in the treatment with CBD regarding anxiety and stress. With 70.6% of positive results in table 3, CBD appears as a promising option in the treatment of anxiety, stress and similar behaviors. Regarding depression, the results were slightly lower. With 66.6% positive results, depression can also be treated with CBD as an alternative therapy option. In dose used CBD administration are extremely diverse. The doses ranged from 25mg to 800mg depending on the time of administration and also the purpose of the therapy. Although the results presented in this study are promising, we need more information to be able to position ourselves on the efficiency of CBD in proposed treatments.
2. Russo EB. Cannabis therapeutics and the future of neurology. Front Integr Neurosci 2018;12:51.
3. Maroon J, Bost J. Review of the neurological benefits of phytocannabinoids. Surg Neurol Int 2018;9:91.
4. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802.
5. Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L. Cannabis sativa L. and non-psychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Res Int 2018;2018:1691428.
6. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007;6:2921-7.
7. Juknat A, Rimmerman N, Levy R, Vogel Z, Kozela E. Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochem Int 2012;61:923-30.
8. Nagarkatti P, Pandey R, Rieder SA, Hegde V, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009;1:1333-49.
9. Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer’s disease. Mol Pharmacol 2011;79:964-73.
10. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Voge Z. Cannabinoids ?9-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-?B and interferon-?/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 2010;285:1616-26.
11. Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch Toxicol 2019;93:179-88.
12. Khoury JM, Neves MC, Roque MA, Queiroz DA, de Freitas AA, de Fátima Â, et al. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry 2019;20:101-16.
13. Crippa JA, Hallak JE, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? Psychiatry Clin Neurosci 2019;269:121-33.
14. Calapai G, annucci C, Chinou I, Cardia L, Calapai F, Sorbara EE, et al. Preclinical and clinical evidence supporting use of cannabidiol in psychiatry. Evid Based Complement Alternat Med 2019;2019:2509129.
15. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D,et al. Cannabidiol reduces A?-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR? involvement. PLoS One 2011;6:e28668.
16. Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O’Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol 2019;85:1888-900.
17. Terluin B, Oosterbaan DB, Brouwers EP, van Straten A, van de Ven PM, Langerak W, et al. To what extent does the four-dimensional symptom questionnaire (4DSQ) anxiety scale detect specific types of anxiety disorder in primary care? A psychometric study. BMC Psychiatry 2014;14:121.
18. Gda?ska P, Drozdowicz-Jastrz?bska E, Grzechoci?ska B, Radziwon-Zaleska M, W?grzyn P, Wielgo? M. Anxiety and depression in women undergoing infertility treatment. Ginekol Pol 2017;88:109-12.
19. Liu L, Liu C, Wang Y, Wang P, Li Y, Li B. Herbal medicine for anxiety, depression, and insomnia. Curr Neuropharmacol 2015;13:481-93.
20. Allan NP, Oglesby ME, Short NA, Schmidt NB. Examining the panic attack specifier in social anxiety disorder. Cogn Behav Ther 2016;45:177-81.
21. Kühlmann AY, de Rooij A, Kroese LF, van Dijk M, Hunink MG, Jeekel J. A meta-analysis evaluating music interventions for anxiety and pain in surgery. Br J Surg 2018;105:773-83.
22. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
23. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
24. De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 2019;160:136-50.
25. Hughes B, Herron CE. Cannabidiol reverses deficits in hippocampal LTP in a model of Alzheimer’s disease. Neurochem Res 2019;44:703-13.
26. Wang Y. PPARs: Diverse regulators in energy metabolism and metabolic diseases. Cell Res 2010;20:124-37.
27. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011;2:236-40.
28. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996;14:649-83.
29. Lawrence T. The nuclear factor NF-?B pathway in inflammation. Cold Spring Harb Perspect Biol 2009;1:a001651.
30. Vallée A, Lecarpentier Y, Guillevin R, Vallée JN. Effects of cannabidiol interactions with Wnt/?-catenin pathway and PPAR? on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim Biophys Sin (Shanghai) 2017;49:853-66.
31. Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures, and reduces stroke damage via the sigma one receptor. Mol Brain 2018;11:51.
32. Roy S, Awasthi H. Herbal medicines as neuroprotective agent: A mechanistic approach. Int J Pharm Pharm Sci 2017;9:1-7.
33. Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Or Fuchs D, et al. Cannabidiol use in children with autism spectrum disorder to treat related symptoms and comorbidities. Front Pharmacol 2018;9:1521.
34. Poleg S, Golubchik P, Offen D, Weizman A. Cannabidiol as a suggested candidate for the treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 2019;89:90-6.
35. Peres FF, Lima AC, Hallak JE, Crippa JA, Silva RH. Cannabidiol as a promising strategy to treat and prevent movement disorders? Front Pharmacol 2018;9:482.
36. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014;24:R453-62.
37. Paul S, Das AP, Bhattacharjee S. Rheumatoid arthritis: Molecular basis and cures from nature. Int J Pharm Pharm Sci 2015;7:30-9.
38. Shannon S, Lewis N, Lee H, Hughes SS. Cannabidiol in anxiety and sleep: A large case series. Perm J 2019;23:18-41.
39. Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol 2019;10:2466.
40. Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry 2019;41:9-14.
41. Schleicher EM, Ott FW, Müller M, Silcher B, Sichler ME, Löw MJ, et al. Prolonged cannabidiol treatment lacks on detrimental effects on memory, motor performance, and anxiety in C57BL/6J mice. Front Behav Neurosci 2019;13:94.
42. Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at high clinical risk of developing psychosis. Psychopharmacology (Berl) 2020;237:1121-30.
43. Zendulka O, Dovrt?lová G, Nosková K, Turjap M, Šulcová A, Hanuš L, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 2016;17:206-26.
44. Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry 2019;176:911-22.
This work is licensed under a Creative Commons Attribution 4.0 International License.